Most cited papers from Affibody (Sweden)

Affibody (Sweden)

What are the most cited papers from Affibody (Sweden)?

The most cited paper from Affibody (Sweden) is "Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications" (John Löfblom, Joachim Feldwisch, Vladimir Tolmachev et al., 2010), with 657 citations. Next come "Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule" (574) and "Protein A chromatography for antibody purification" (561).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 60 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications John Löfblom, Joachim Feldwisch, Vladimir Tolmachev et al. · FEBS Letters Open access	11 Apr 2010	657
2	Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule Anna Orlova, Mikaela Magnusson, Tove Lisa Jenny Eriksson et al. · Cancer Research Open access	15 Apr 2006	574
3	Protein A chromatography for antibody purification Sophia Hober, Karin Nord, Martin Linhult · Journal of Chromatography B	10 Oct 2006	561
4	Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation Wolfgang Hoyer, Caroline Grönwall, Andreas Jonsson et al. · Proceedings of the National Academy of Sciences Open access	29 Mar 2008	418
5	Affibody Molecules in Biotechnological and Medical Applications Stefan Ståhl, Torbjörn Gräslund, Amelie Eriksson Karlström et al. · Trends in biotechnology Review	14 May 2017	394
6	Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules Richard Paul Baum, Vikas Prasad, Dirk Müller et al. · Journal of Nuclear Medicine Open access	19 May 2010	310
7	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [ 68 Ga]ABY-025 Affibody PET/CT Jens Nørkær Sørensen, Irina Velikyan, Dan Sandberg et al. · Theranostics Open access	31 Dec 2015	272
8	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule Jens Sørensen, Dan Sandberg, Mattias Sandström et al. · Journal of Nuclear Medicine Open access	24 Mar 2014	263
9	Structural basis for high-affinity HER2 receptor binding by an engineered protein Charles W. Eigenbrot, Mark H. Ultsch, Anatoly P. Dubnovitsky et al. · Proceedings of the National Academy of Sciences Open access	9 Aug 2010	238
10	Engineering of a femtomolar affinity binding protein to human serum albumin Anders P. Jonsson, Jakob Dogan, Nina Herne et al. · Protein Engineering Design and Selection	13 May 2008	236
11	Affibody molecules as engineered protein drugs Fredrik Y. Frejd, Kyu‐Tae Kim · Experimental & Molecular Medicine Open access	24 Mar 2017	230
12	Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule Vladimir Tolmachev, Anna Orlova, Rikard Pehrson et al. · Cancer Research	15 Mar 2007	219
13	Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Anna Orlova, Vladimir Tolmachev, Rikard Pehrson et al. · Cancer Research Open access	Mar 2007	193
14	Design of an Optimized Scaffold for Affibody Molecules Joachim Feldwisch, Vladimir Tolmachev, Christofer Lendel et al. · Journal of Molecular Biology	11 Mar 2010	188
15	Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule Mikaela Friedman, Anna Orlova, Eva Johansson et al. · Journal of Molecular Biology	7 Jan 2008	176
16	Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain Jan Terje Andersen, Rikard Pehrson, Vladimir Tolmachev et al. · Journal of Biological Chemistry Open access	7 Dec 2010	175
17	Non-immunoglobulin based protein scaffolds John Löfblom, Fredrik Y. Frejd, Stefan Ståhl · Current Opinion in Biotechnology Review	5 Jul 2011	149
18	On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model Anna Orlova, Helena Wållberg, Sharon Stone‐Elander et al. · Journal of Nuclear Medicine Open access	17 Feb 2009	146
19	Slow Internalization of Anti-HER2 Synthetic Affibody Monomer 111 In-DOTA-Z HER2:342-pep2 : Implications for Development of Labeled Tracers Helena Wållberg, Anna Orlova · Cancer Biotherapy and Radiopharmaceuticals	Aug 2008	138
20	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology Ahmet Krasniqi, Matthias D’Huyvetter, Nick Devoogdt et al. · Journal of Nuclear Medicine Open access	15 Mar 2018	134
21	Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy Vladimir Tolmachev, Anna Orlova, Fredrik Y. Nilsson et al. · Expert Opinion on Biological Therapy	21 Mar 2007	131
22	Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor Mikaela Friedman, Erika Nordberg, Ingmarie Höidén‐Guthenberg et al. · Protein Engineering Design and Selection Open access	2007	130
23	Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides Caroline Grönwall, Andreas Jonsson, Sara Lindström et al. · Journal of Biotechnology	28 Sep 2006	127
24	Affinity Proteomics for Systematic Protein Profiling of Chromosome 21 Gene Products in Human Tissues Charlotta Agaton, Joakim Galli, Ingmarie Höidén Guthenberg et al. · Molecular & Cellular Proteomics Open access	Jun 2003	125
25	Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach Martin Linhult, Susanne Gülich, Torbjörn Gräslund et al. · Proteins Structure Function and Bioinformatics	27 Feb 2004	122
26	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount Vladimir Tolmachev, Daniel Rosik, Helena Wållberg et al. · European Journal of Nuclear Medicine and Molecular Imaging	16 Oct 2009	119
27	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients Mattias Sandström, K. Lindskog, Irina Velikyan et al. · Journal of Nuclear Medicine Open access	9 Feb 2016	114
28	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry Vladimir Tolmachev, Mikaela Friedman, Mattias Sandström et al. · Journal of Nuclear Medicine Open access	21 Jan 2009	114
29	Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine Sara C. Ahlgren, Helena Wållberg, Thuy Tran et al. · Journal of Nuclear Medicine Open access	16 Apr 2009	114
30	99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors Thuy Tran, Torun Engfeldt, Anna Orlova et al. · Bioconjugate Chemistry	19 Oct 2007	108
31	Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Fredrik Y. Nilsson, Vladimir Tolmachev · PubMed	Mar 2007	107
32	In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics Ann-Charlott Steffen, Maria Wikman, Vladimir Tolmachev et al. · Cancer Biotherapy and Radiopharmaceuticals	Jun 2005	102
33	In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET D. E. González Trotter, Xiangjun Meng, Paul S. Mcquade et al. · Journal of Nuclear Medicine	6 Jun 2017	101
34	Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold Sara C. Ahlgren, Anna Orlova, Helena Wållberg et al. · Journal of Nuclear Medicine Open access	16 Jun 2010	100
35	Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules Sara C. Ahlgren, Anna Orlova, Daniel Rosik et al. · Bioconjugate Chemistry	29 Dec 2007	99
36	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence Torun Engfeldt, Anna Orlova, Thuy Tran et al. · European Journal of Nuclear Medicine and Molecular Imaging	4 Dec 2006	99
37	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule Torun Engfeldt, Thuy Tran, Anna Orlova et al. · European Journal of Nuclear Medicine and Molecular Imaging	12 Jun 2007	97
38	Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein Anna Orlova, Andreas Jonsson, Daniel Rosik et al. · Journal of Nuclear Medicine Open access	25 Mar 2013	91
39	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Anna Orlova, Fredrik Y. Nilsson, Maria Wikman et al. · PubMed	Mar 2006	90
40	Engineering of Affibody Molecules for Therapy and Diagnostics Joachim Feldwisch, Vladimir Tolmachev · Methods in molecular biology Book chapter	2012	90
41	Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In Vivo Malin Lindborg, Eliane Cortez, Ingmarie Höidén‐Guthenberg et al. · Journal of Molecular Biology	29 Jan 2011	88
42	Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use Kimberley S. Samkoe, Jason R. Gunn, Kayla A. Marra et al. · Molecular Imaging and Biology Open access	Dec 2016	87
43	A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry Nina Kronqvist, John Löfblom, Anders P. Jonsson et al. · Protein Engineering Design and Selection	31 Jan 2008	87
44	HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [99mTc(CO)3]+, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation Vladimir Tolmachev, Camilla Hofström, Jennie Malmberg et al. · Bioconjugate Chemistry	22 Oct 2010	84
45	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake Torun Ekblad, Thuy Tran, Anna Orlova et al. · European Journal of Nuclear Medicine and Molecular Imaging	Jul 2008	81
46	Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules Nina Kronqvist, Magdalena Malm, Lovisa Göstring et al. · Protein Engineering Design and Selection	21 Dec 2010	80
47	Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule Erika Nordberg, Mikaela Friedman, Lovisa Göstring et al. · Nuclear Medicine and Biology	Aug 2007	78
48	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification Magdalena Malm, Nina Kronqvist, Hanna Lindberg et al. · PLoS ONE Open access	10 May 2013	73
49	Engineering streptococcal protein G for increased alkaline stability Susanne Gülich, Martin Linhult, Stefan Ståhl et al. · Protein Engineering Design and Selection	Oct 2002	72
50	Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer Anna Orlova, Joachim Feldwisch, Lars Abrahmsén et al. · Cancer Biotherapy and Radiopharmaceuticals	Oct 2007	69

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.